Evidence map›Paper›PMID 31413595›Full record

ArticleOncoTargets and therapy2019

The role of PEG3 in the occurrence and prognosis of colon cancer.

Ting Zhou, Wei Lin, Qiongni Zhu, Helen Renaud, Xiaowei Liu, Ruidong Li, Cui Tang, Chong Ma, Tai Rao, Zhirong Tan and 1 more

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Expression and methylation status ofGastroenterology and hepatology from bed to bench · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Ting ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Qiongni ZhuDepartment of Pharmacy, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, People's Republic of China.
Helen RenaudDepartment of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Xiaowei LiuDepartment of Gastroenterology, Xiangya Hospital of Central South University, Changsha, Hunan 410008, People's Republic of China.
Ruidong LiGraduate Program in Genetics, Genomics & Bioinformatics, University of California, Riverside, CA 92507, USA.
Cui TangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Chong MaDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Tai RaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Zhirong TanDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Ying GuoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, People's Republic of China.
Central South University · CNShanghai Jiao Tong University · CNUniversity of California, Riverside · USUniversity of Kansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeImprinted genes are often identified as key players in the etiology and prognosis of many tumors; however, the role they play in colon cancer remains unclear. Along with the development of big data analysis came the discovery of a wealth of genetic prognostic factors, like microsatellite instability for colon cancer, which need to be taken into consideration when evaluating new biomarkers for the disease.

methodsWe systematically mined public databases to find recurrence free survival (RFS)-related imprinted genes for colon cancer patients on the mRNA level by univariate and multivariate survival analyses. We then investigated the association of methylation status and microRNA expression of the targeted imprinted genes with survival rate of colon cancer patients. Lastly, in a clinical study we used qRT-PCR and immunohistochemistry to quantify mRNA and protein expression of the imprinted genes that related to RFS in our bioinformatics screening, respectively, in 20 tumor tissues compared to paired adjacent tissues.

resultsThe results show that paternally expressed gene 3 (PEG3) is the only imprinted gene related to colon cancer patient prognosis on the mRNA level in our datasets, and high mRNA expression of PEG3 is associated with a poor prognosis. Furthermore, the methylation beta value of cg13960339, as well as the expression of 4 microRNAs, negatively correlated with PEG3 mRNA level and were correlated with the prognosis of colon cancer patients. Moreover, the expression of PEG3 mRNA in colon cancer is significantly lower, but PEG3 protein expression is significantly higher compared to that in normal tissues.

conclusionPEG3 is likely associated with the progression and prognosis of colon cancer.

Indexed as

colon cancerimprinted genePEG3prognosis

Identifiers

PMID31413595
PMCPMC6662866
OpenAlexW2963073107

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.